Anti-uPAR / PLAUR Magnetic Beads Immunoprecipitation (IP) Kit

Price:
Size:
Number:

Anti-uPAR / PLAUR Magnetic Beads-IP Kit Product Components

Components Storage
Anti-uPAR / PLAUR Magnetic Beads1,3 2-8℃ for 12 months
NP40 Cell Lysis Buffer2 -20℃ for 12 months
5×TBST(pH7.4)  
1×TBST(pH7.4)  
ddH2O  
Alkaline Elution Buffer 2-8℃ for 12 months
Acidity Elution Buffer 2-8℃ for 12 months
Neutralization Buffer 2-8℃ for 12 months

【1】The IP KIT contains anti-uPAR / PLAUR magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).

【2】Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.

【3】Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.

Anti-uPAR / PLAUR Magnetic Beads-IP Kit Product Description

The Anti-uPAR / PLAUR magnetic Beads, conjugated with Anti-uPAR / PLAUR antibody, are used for immuneprecipitation (IP) of uPAR / PLAUR proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing uPAR / PLAUR proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound uPAR / PLAUR proteins are dissociated from the magnetic beads using an elution buffer.

Anti-uPAR / PLAUR Magnetic Beads-IP Kit Antibody Information

Antibody
Anti-uPAR / PLAUR Antibody(10925-T30)
Immunogen
Recombinant Human uPAR/PLAUR Protein (Catalog#10925-H08H)
Species Reactivity
Human uPAR/PLAUR
Source
Polyclonal Human Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Human uPAR/PLAUR (rh uPAR/PLAUR; Catalog#10925-H08H; Q03405-1; Met1-Arg303). uPAR/PLAUR specific IgG was purified by Human uPAR/PLAUR affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification

Anti-uPAR / PLAUR Magnetic Beads Immunoprecipitation (IP) Kit: Alternative Names

Anti-CD87ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-U-PARALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-UPARALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit; Anti-URKRALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit

uPAR / PLAUR Background Information

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-6kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.
Full Name
plasminogen activator, urokinase receptor
References
  • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
  • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
  • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
  • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait